Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Filgrastim

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    Study title: Michon JM et al, An open-label, multicentre, randomised phase 2 study of recombinant human, granulocyte colony-stimulating factor (filgrastim) as an adjunct to combination, chemotherapy in paediatric patients with metastatic neuroblastoma, Eur J Cancer. 1998 Jun;34(7):1063-9
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26944
    Study title: Anderson, R. A., Corr, T. R., Hewitt, L. A., et al. A phase II study of filgrastim-mobilized peripheral blood progenitor cells (PBPC) infusion support for relapsed pediatric solid tumors being treated with ifosfamide, carboplatin and etoposide (ICE) Blood 90(10 SUPPL: 15, 1997.Anderson, R. A., Corr, T. R., Hewitt, L. A., et al. A phase II study of filgrastim-mobilized peripheral blood progenitor cells (PBPC) infusion support for relapsed pediatric solid tumors being treated with ifosfamide, carboplatin and etoposide (ICE) Blood 90(10 SUPPL: 15, 1997.
    Active substance: FILGASTRIM
    Study summary document link (including results):
    View full study record
    Document reference: 27282
    Study title: Rahiala, J., Perkkio, M. and Riikonen, P. Prospective and randomized comparison of early versus delayed prophylactic administration of granulocyte colony-stimulating factor (filgrastim) in children with cancer Medical & Pediatric Oncology 32(5): 326-30.Rahiala, J., Perkkio, M. and Riikonen, P. Prospective and randomized comparison of early versus delayed prophylactic administration of granulocyte colony-stimulating factor (filgrastim) in children with cancer Medical & Pediatric Oncology 32(5): 326-30.
    Active substance: FILGASTRIM
    Study summary document link (including results):
    View full study record
    Document reference: 27280
    Study title: Michon JM et al. An open-label, multicentre, randomised phase 2 study of recombinant human granulocyte colony-stimulating factor (filgrastim) as an adjunct to combination chemotherapy in paediatric patients with metastatic neuroblastoma. Eur J Cancer. 1998 Jun;34(7):1063-9Michon JM et al. An open-label, multicentre, randomised phase 2 study of recombinant human granulocyte colony-stimulating factor (filgrastim) as an adjunct to combination chemotherapy in paediatric patients with metastatic neuroblastoma. Eur J Cancer. 1998 Jun;34(7):1063-9
    Active substance: CYCLOPHOSPHAMIDE
    Study summary document link (including results):
    View full study record
    Document reference: 25024
    Study title: Once-per-cycle pegfilgrastim versus daily filgrastim in pediatric patients with Ewing sarcoma. Wendelin, G. et al. Journal of Pediatric Hematology/Oncology 27(8): 449-51.Once-per-cycle pegfilgrastim versus daily filgrastim in pediatric patients with Ewing sarcoma. Wendelin, G. et al. Journal of Pediatric Hematology/Oncology 27(8): 449-51.
    Active substance: pegfilgrastim
    Study summary document link (including results):
    View full study record
    Document reference: 41579
    Study title: Michon JM et al. An open-label, multicentre, randomised phase 2 study of recombinant human granulocyte colony-stimulating factor (filgrastim) as an adjunct to combination chemotherapy in paediatric patients with metastatic neuroblastoma. Eur J Cancer. 1998 Jun;34(7):1063-9Michon JM et al. An open-label, multicentre, randomised phase 2 study of recombinant human granulocyte colony-stimulating factor (filgrastim) as an adjunct to combination chemotherapy in paediatric patients with metastatic neuroblastoma. Eur J Cancer. 1998 Jun;34(7):1063-9
    Active substance: MITOXANTRONE
    Study summary document link (including results):
    View full study record
    Document reference: 32240
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 14 10:42:47 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA